- Kidney rejection initiated by antibodies that were present before transplantation is linked with a better outcome that rejection due to antibodies that arise after transplantation.
Washington, DC (March 2, 2017) -- New research provides insights on transplant recipients' antibody responses against donor kidneys and how the timing of those responses can have important implications. The findings appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
An antibody response against donor organs is the main cause of kidney rejection following transplantation. Antibodies can occur in 2 scenarios: before transplantation (pre-existing donor-specific antibodies) and after transplantation (de novo donor-specific antibodies). Little is known about how these processes compare.
Understanding the role of antibodies in transplant rejection is needed to guide matching of donors and recipients and to better prevent rejection. A team led by Alexandre Loupy, MD, PhD, Olivier Aubert, MD (INSERM U 970, Paris Translational Research Center for Organ Transplantation, in France), and Phil Halloran, MD, PhD (Alberta Transplant Applied Genomics Centre, in Canada) studied 205 patients who experienced antibody-mediated rejection following kidney transplantation: 103 patients had pre-existing donor-specific antibodies and 102 patients had de novo donor-specific antibodies.
There were various differences between patients with pre-existing vs. de novo donor-specific antibodies, but the most striking was the superior kidney survival experienced by the pre-existing group compared with the de novo group (63% vs. 34% at 8 years after rejection, respectively), regardless of treatment.
"Our study highlights that rejection due to antibodies that were present before transplantation is linked with a significantly better outcome that rejection due to de novo donor-specific antibodies," said Dr. Aubert.
"Our results encourage the transplantation of patients who have antibodies before transplant. These patients would not normally have been considered as good candidates for transplantation and would have stayed on dialysis because of a high level of sensitization that prevents from finding a compatible kidney," said Dr. Loupy. The findings also indicate the need to closely monitor patients for the development of de novo donor-specific antibodies so that therapies can be initiated to preserve kidney function.
Study co-authors include Luis Hidalgo, PhD, Jean-Paul Duong van Huyen, MD, PhD, Sarah Higgins, MD, Denis Viglietti, MD, Xavier Jouven, MD, PhD, Denis Glotz, MD, PhD, Christophe Legendre, MD, and Carmen Lefaucheur, MD, PhD.
Disclosures: Dr. Halloran holds shares in and is CEO of Transcriptome Sciences Inc., a company with an interest in molecular diagnostics. The other authors have no competing financial interests.
The article, entitled "Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients," will appear online at http://jasn.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 17,000 members representing 112 countries. For more information, please visit http://www.